Iveric, Astellas eye US label expansion for geographic atrophy drug after positive two-year data
Iveric Bio and Astellas Pharma’s Izervay has shown longer-term efficacy promise in geographic atrophy (GA), paving the way for a US label expansion aimed at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.